Sinopep Allsino Bio Pharmaceutical Co (SHSE:688076) Revenue: ¥2,034 Mil (TTM As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SHSE:688076 Sinopep Allsino Bio Pharmaceutical Co Ltd SHSE:688076
75 GF Score
Price ¥27.65
GF Value ¥54.05
Valuation Significantly Undervalued
! 7 Warning Signs
View Full Analysis

What is Sinopep Allsino Bio Pharmaceutical Co Revenue?

Sinopep Allsino Bio Pharmaceutical Co SHSE:688076 +0.33% 75 Revenue is ¥2,034 Mil as of Jun. 2026. GuruFocus rates SHSE:688076 with a GF Score™ of 75/100 and a GF Value™ of ¥54.05 (Significantly Undervalued). The stock has 7 warning signs investors should review.

Sinopep Allsino Bio Pharmaceutical Co's revenue for the three months ended in Jun. 2026 was ¥587 Mil. Its revenue for the trailing twelve months (TTM) ended in Jun. 2026 was ¥2,034 Mil. Sinopep Allsino Bio Pharmaceutical Co's Revenue per Share for the three months ended in Jun. 2026 was ¥1.85. Its Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2026 was ¥6.45.

During the past 12 months, the average Revenue per Share Growth Rate of Sinopep Allsino Bio Pharmaceutical Co was 10.90% per year. During the past 3 years, the average Revenue per Share Growth Rate was 26.60% per year. During the past 5 years, the average Revenue per Share Growth Rate was 19.10% per year. During the past 10 years, the average Revenue per Share Growth Rate was 44.10% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate using Revenue per Share data.

During the past 13 years, Sinopep Allsino Bio Pharmaceutical Co's highest 3-Year average Revenue per Share Growth Rate was 150.70% per year. The lowest was 10.90% per year. And the median was 24.85% per year.


Sinopep Allsino Bio Pharmaceutical Co  (SHSE:688076) Revenue Explanation

In ranking the predictability, companies with more consistent revenue and earnings growth are ranked high with predictability.

Peter Lynch categorized companies according to their revenue growth:


Slow Grower: Inflation < 10-Year Revenue Growth Rate < 10%:
Stalwart: 10% < 10-Year Revenue Growth Rate < 20%:
Fast Grower: 10-Year Revenue Growth Rate > 20%:

His favorite companies are stalwart, those growing between 10-20% a year.

Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.


Be Aware

Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.


Sinopep Allsino Bio Pharmaceutical Co Revenue Related Terms


Sinopep Allsino Bio Pharmaceutical Co Revenue Historical Data

* Premium members only.

The historical data trend for Sinopep Allsino Bio Pharmaceutical Co's Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sinopep Allsino Bio Pharmaceutical Co Revenue Chart

Sinopep Allsino Bio Pharmaceutical Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 613.87 651.29 1,033.55 1,624.80 1,942.80

Sinopep Allsino Bio Pharmaceutical Co Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 482.68 478.90 415.62 552.98 586.67

SHSE:688076 vs VRTX, REGN, RVMD: Revenue Comparison

For the Biotechnology subindustry, Sinopep Allsino Bio Pharmaceutical Co's Revenue, along with its competitors' market caps and Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sinopep Allsino Bio Pharmaceutical Co Revenue vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Sinopep Allsino Bio Pharmaceutical Co's Revenue distribution charts can be found below:

* The bar in red indicates where Sinopep Allsino Bio Pharmaceutical Co's Revenue falls into.


SHSE:688076
75GF Score
Sinopep Allsino Bio Pharmaceutical Co Ltd SHSE:688076
Revenue is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Sinopep Allsino Bio Pharmaceutical Co Revenue Calculation

Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.

Revenue for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥2,034 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Revenue →
What does a Revenue of ¥2,034 Mil mean?
Sinopep Allsino Bio Pharmaceutical Co (SHSE:688076) has a Revenue of ¥2,034 Mil as of Jun. 2026. Revenue is the total amount a company generates as sales through its operations. View historical data on Sinopep Allsino Bio Pharmaceutical Co and its competitors.
Is Sinopep Allsino Bio Pharmaceutical Co's Revenue too high?
Sinopep Allsino Bio Pharmaceutical Co's current Revenue is ¥2,034 Mil. Overall, Sinopep Allsino Bio Pharmaceutical Co has a GF Score™ of 75/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Sinopep Allsino Bio Pharmaceutical Co's Revenue compare to VRTX and REGN?
Sinopep Allsino Bio Pharmaceutical Co's Revenue of ¥2,034 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Revenue for a Biotechnology company?
A good Revenue depends on the Biotechnology industry context. However, Revenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Revenue mean?
A high Revenue can signal that a stock is expensive relative to its fundamentals. Revenue is the total amount a company generates as sales through its operations. View historical data on Sinopep Allsino Bio Pharmaceutical Co and its competitors. Sinopep Allsino Bio Pharmaceutical Co's current Revenue is ¥2,034 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sinopep Allsino Bio Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Sinopep Allsino Bio Pharmaceutical Co (SHSE:688076) is currently considered Significantly Undervalued. The stock's GF Value™ is ¥54.05, compared to a current price of ¥27.65 — trading 48.8% below its estimated fair value. The current Revenue is ¥2,034 Mil. Sinopep Allsino Bio Pharmaceutical Co's overall GF Score™ is 75/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Revenue calculated?
Revenue is calculated from a company's financial statements. For Sinopep Allsino Bio Pharmaceutical Co (SHSE:688076), the current Revenue is ¥2,034 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Sinopep Allsino Bio Pharmaceutical Co (SHSE:688076) Overvalued in 2026?

Based on GuruFocus' analysis, Sinopep Allsino Bio Pharmaceutical Co stock appears to be undervalued. The current stock price of ¥27.65 is trading 48.8% below its estimated GF Value™ of ¥54.05. GuruFocus considers Sinopep Allsino Bio Pharmaceutical Co to be Significantly Undervalued.

Key valuation signals for SHSE:688076:

  • Revenue: ¥2,034 Mil
  • GF Value™: ¥54.05 vs. price of ¥27.65 (48.8% below fair value)
  • GF Score™: 75/100 with 7 warning signs

No single metric tells the full story. See the SHSE:688076 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Sinopep Allsino Bio Pharmaceutical Co Business Description

Address No. 28, Linpu Road, Economic and Technological Development Zone, Jiangsu Province, Lianyungang, CHN, 222069
Sinopep Allsino Bio Pharmaceutical Co Ltd is a market-oriented, research and development and innovation-driven biomedical enterprise focusing on the research, development, production and sales of peptide drugs and small molecule chemical drugs.
75GF Score

Get the complete analysis for SHSE:688076

Revenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥27.65
Price
¥54.05
GF Value